Literature DB >> 2161929

A Fabry's disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations.

L Hasholt1, S A Sørensen, A Wandall, E B Andersen, P Arlien-Søborg.   

Abstract

A Fabry heterozygote with early clinical manifestations of this X linked disorder is described. Her symptoms, including febrile attacks, arthralgia, abdominal pain, and neurological signs, were characteristic of Fabry's disease hemizygotes. The neurological findings were compatible with a brain stem infarction. The diagnosis was confirmed by the finding of low activities of alpha-galactosidase A (alpha-galA) in plasma, lymphocytes, and cultured fibroblasts, and by the observation of typical lamellar inclusions in the lysosomes of cultured fibroblasts. Increased levels of ceramide trihexoside were also found by TLC of urine sediment. The family history gave no indication of Fabry's disease in the patient's relatives, and biochemical and ultrastructural investigations of their cells were also normal. Our findings therefore suggest that the defective gene in the heterozygote has resulted from a new mutation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161929      PMCID: PMC1017080          DOI: 10.1136/jmg.27.5.303

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  20 in total

1.  Detection of Fabry's disease heterozygotes by hair root analysis.

Authors:  A L Beaudet; C T Caskey
Journal:  Clin Genet       Date:  1978-03       Impact factor: 4.438

2.  Neurological manifestations of Fabry disease in female carriers.

Authors:  T D Bird; D Lagunoff
Journal:  Ann Neurol       Date:  1978-12       Impact factor: 10.422

3.  The abbreviated PR interval of Fabry's disease.

Authors:  C P Roudebush; J M Foerster; O H Bing
Journal:  N Engl J Med       Date:  1973-08-16       Impact factor: 91.245

4.  Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes.

Authors:  R J Desnick; K Y Allen; S J Desnick; M K Raman; R W Bernlohr; W Krivit
Journal:  J Lab Clin Med       Date:  1973-02

5.  Magnetic resonance imaging in Fabry's disease.

Authors:  D G Menzies; I W Campbell; D M Kean
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-09       Impact factor: 10.154

6.  Fabry disease: molecular diagnosis of hemizygotes and heterozygotes.

Authors:  R J Desnick; H S Bernstein; K H Astrin; D F Bishop
Journal:  Enzyme       Date:  1987

7.  Heterozygote detection in Fabry disease utilizing multiple enzyme activities.

Authors:  K J Sheth; T A Good; J V Murphy
Journal:  Am J Med Genet       Date:  1981

8.  Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease.

Authors:  J S Mayes; J B Scheerer; R N Sifers; M L Donaldson
Journal:  Clin Chim Acta       Date:  1981-05-05       Impact factor: 3.786

9.  Evidence for preferential X-chromosome inactivation in a family with Fabry disease.

Authors:  H H Ropers; T F Wienker; T Grimm; K Schroetter; K Bender
Journal:  Am J Hum Genet       Date:  1977-07       Impact factor: 11.025

10.  Electroencephalographic and electromyographic changes in a case of angiokeratoma corporis diffusum (Fabry's disease).

Authors:  S L Visser; W P de Groot
Journal:  Confin Neurol       Date:  1970
View more
  2 in total

Review 1.  Neurology and the skin.

Authors:  O Hurko; T T Provost
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-04       Impact factor: 10.154

2.  Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.

Authors:  C Whybra; C Kampmann; I Willers; J Davies; B Winchester; J Kriegsmann; K Brühl; A Gal; S Bunge; M Beck
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.